Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
AURIGA subgroup analysis finds dara/len maintenance in NDMM -> higher MRD (10-5) conversion at 12 months in original high-risk (31.8 vs 6.7%), revised (43.8 vs 13.3%), and modified IMS 2024 (41.2 vs 0%) and ultra-high-risk (54.5 vs 0%).”
Title: Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
Authors: Laahn Foster, Larry D. Anderson Jr, Alfred Chung, Chakra P. Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Peter Voorhees, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
